Products

CorVista System with PH Add-On
CorVista Health
Cardiology AI
The CorVista System with PH Add-On is an FDA-cleared, non-invasive, point-of-care AI diagnostic platform for rapid assessment of coronary artery disease and pulmonary hypertension using machine-learned algorithms.

See all 1 product →

About Analytics for Life

Analytics for Life (also known as Analytics 4 Life) is a digital health company that leverages artificial intelligence, machine learning, and cloud computing to develop innovative diagnostic solutions, primarily for cardiovascular diseases. Their flagship product, the CorVista System®, is a non-invasive, point-of-care diagnostic test designed to assess symptomatic patients for coronary artery disease (CAD) and pulmonary hypertension (PH) without the need for radiation, contrast agents, injections, fasting, or exercise. [3, 4, 5, 7, 14, 15] The system works by scanning intrinsic signals emitted by the human body, which are then transmitted to the cloud for analysis by machine-learned algorithms. [4, 5, 15] This process generates a unique image and a heart model, indicating areas of potential heart disease, with results accessible to physicians via a secure web portal to aid in diagnosis and treatment decisions. [4, 5, 15]

The company’s approach aims to revolutionize cardiovascular care by providing a more efficient, less risky, and cost-effective alternative to traditional diagnostic methods like myocardial perfusion imaging (MPI) and coronary computed tomographic angiography (CCTA). [3, 4, 5] The CorVista System has been cleared by the FDA for marketing within the U.S. for CAD and PH. [3] Analytics for Life emphasizes improving access to life-saving healthcare products, particularly in rural and resource-constrained environments where access to capital-intensive equipment and specialists may be limited. [3, 7] Beyond cardiovascular diagnostics, Analytics for Living (a related entity or broader vision) also applies machine learning and AI to financial services (including financial crime prevention) and hospitality, with a mission to improve access to life-saving innovations and optimize supply solutions. [2, 6]

Focus Areas

non-invasive cardiovascular diagnostics artificial intelligence machine learning coronary artery disease pulmonary hypertension heart failure

Business Intelligence

TechnologyCloud-based platform, Phase Space Tomography technology, AI-based algorithms, machine learning

What Physicians Need to Know

Specialization
Analytics for Life specializes in non-invasive cardiovascular diagnostics, focusing on conditions such as coronary artery disease (CAD), pulmonary hypertension (PH), and heart failure (HFpEF, HFrEF). They aim to revolutionize point-of-care diagnostics for these conditions.
Key Differentiator: Non-Invasive Diagnostics
Their flagship product, the CorVista System, is a non-invasive, point-of-care test that assesses symptomatic patients for cardiovascular disease without the need for radiation, contrast agents, injections, fasting, or exercise.
Key Differentiator: Speed and Efficiency
The CorVista System aims to significantly reduce the time it takes to diagnose cardiovascular conditions, providing results within minutes. This contrasts with traditional diagnostic methods that can take weeks and involve multiple procedures.
Technology Stack: AI and Machine Learning
The CorVista platform is built on proprietary Phase Space Tomography technology and leverages artificial intelligence (AI) and machine learning (ML) algorithms to analyze physiological signals emitted by the heart.
Technology Stack: Cloud-Based Analysis
Patient scan data is sent to the cloud, where Analytics for Life's software analyzes it using machine-learned algorithms to create a 3D model of the heart and identify potential areas of disease.
Diagnostic Capabilities
The CorVista System is FDA-cleared for coronary artery disease and pulmonary hypertension, with ongoing development for heart failure indications, including the ability to indicate the likelihood of elevated Pulmonary Capillary Wedge Pressure (PCWP).
Physician Tip

For physicians, Analytics for Life's CorVista System offers a rapid, non-invasive, and radiation-free method for assessing patients with suspected cardiovascular conditions like CAD, PH, and heart failure. This can lead to earlier and more accurate diagnoses, potentially reducing the need for invasive testing and accelerating treatment decisions. The system provides actionable insights at the point of care, which, when combined with a patient's medical history and symptoms, can guide treatment pathways and improve patient outcomes. The ability to quickly identify elevated PCWP, a key indicator for heart failure, is particularly valuable for timely intervention in conditions that are often underdiagnosed.

The CorVista System is designed as a point-of-care solution, providing analysis results via a secure web portal. This suggests a focus on direct integration into clinical workflows for immediate access to diagnostic information. The economic analysis highlights its seamless integration into existing cardiovascular diagnostic workflows and its potential to offer significant cost savings by preventing delays in treatment.

Products by Analytics for Life

1 product in the directory

CorVista System with PH Add-On
CorVista Health
Cardiology AI
The CorVista System with PH Add-On is an FDA-cleared, non-invasive, point-of-care AI diagnostic platform for rapid assessment of coronary artery disease and pulmonary hypertension using machine-learned algorithms.

What the Web Says

Analytics for Life appears to be a company focused on developing innovative diagnostic tools, particularly in the healthcare sector, utilizing machine learning. The provided news release highlights their completion of a clinical study for a non-invasive point-of-care test for elevated pulmonary capillary wedge pressure. Due to the highly specialized nature of their work and the limited public information available from general review sites, comprehensive product and employer reviews are scarce.

Overall: Mixed

Strengths

  • Innovative application of machine learning in healthcare diagnostics
  • Focus on non-invasive diagnostic solutions
  • Addresses a critical medical need (PCWP detection)
  • Successful completion of a clinical study (as per news release)
  • Potential for significant impact on patient care

Limitations

  • Limited public reviews available on common platforms (G2, Glassdoor, Capterra)
  • Specific product details and availability are not widely publicized yet
  • No readily available employer reviews to assess company culture or work environment
  • Potential for long development and regulatory approval cycles in healthcare
  • Information primarily from a single press release, limiting broader perspective

Based on reviews from: GlobeNewswire (news release), G2 (no relevant reviews found), Glassdoor (no relevant reviews found), Capterra (no relevant reviews found), Reddit (no relevant discussions found), Healthcare IT Reviewers (no specific reviews found for this company/product yet)

Last updated: 2026-10-27

Videos

News, demos, and interviews about Analytics for Life.

Loading videos...

Videos load interactively. If none appear, search YouTube for Analytics for Life →

View all on YouTube

Press & Coverage

Business Wire
FDA Clears CorVista® System PCWP Add-On as a Noninvasive Test For Elevated Pulmonary Capillary Wedge Pressure
Analytics For Life and CorVista Health announced FDA clearance of the CorVista® System with a Pulmonary Capillary Wedge Pressure (PCWP) Add-On, a non-invasive AI-based test for elevated PCWP, a key indicator of heart failure.
2026-07
cardiacvascularnews.com
FDA Clears CorVista® System PCWP Add-On as a Noninvasive Test For Elevated Pulmonary Capillary Wedge Pressure - Cardiac Vascular News
The FDA has cleared the CorVista® System with Pulmonary Capillary Wedge Pressure (PCWP) Add-On, developed by Analytics For Life and CorVista Health, to noninvasively indicate the likelihood of elevated PCWP in symptomatic patients.
2026-07
patientcareonline.com
FDA clears CorVista System PCWP Add-On as a noninvasive test for elevated pulmonary capillary wedge pressure
The FDA has cleared CorVista Health's Pulmonary Capillary Wedge Pressure (PCWP) Add-On for the CorVista System, an AI-based tool designed to noninvasively indicate the likelihood of elevated PCWP in patients with cardiovascular symptoms.
2026-07
GlobeNewswire
Analytics For Life Completes Clinical Study of Non-Invasive Point-of-Care Test for Elevated Pulmonary Capillary Wedge Pressure (PCWP) Using Machine Learning
Analytics For Life, in collaboration with CorVista Health, announced the successful completion of a clinical study evaluating a machine learning-based algorithm for non-invasively identifying patients with elevated pulmonary capillary wedge pressure (PCWP).
2025-08
Business Wire
AI Strengthens Analytics for Life Sciences, Healthcare
A new ISG report indicates that life sciences and healthcare enterprises are increasing investments in advanced analytics, with AI and generative AI playing a crucial role in understanding customer needs and making informed decisions.
2024-10
Financial Post
Analytics for Life and CorVista Health Announce the Publication of their Cost Economic Analysis for Non-Invasive Coronary Artery Disease Testing in the Journal of Visualized Experiments
Analytics for Life and CorVista Health published a cost economic analysis of their non-invasive point-of-care test for Coronary Artery Disease (CAD) in the Journal of Visualized Experiments (JoVE), highlighting its economic benefits and seamless integration into CVD diagnostic workflows.
2024-08
BioSpace
Analytics for Life, Inc. and CorVista Health Inc. Announce FDA Clearance of the CorVista System with Pulmonary Hypertension (PH) Add-On Module
Analytics for Life, Inc. and CorVista Health Inc. announced FDA clearance of the CorVista System with a Pulmonary Hypertension (PH) Add-On Module, expanding its diagnostic capabilities for cardiovascular conditions.
2024-04
FinSMEs
CorVista Health Closes $65M Series C Equity Funding
CorVista Health, a subsidiary of Analytics For Life Inc., closed a $65 million Series C equity financing round, bringing its total funding to nearly $100 million, to accelerate product development for the CorVista System.
2021-03

Frequently Asked Questions

Analytics for Life develops AI-powered non-invasive diagnostic tools for cardiovascular conditions. Our technology analyzes various data points to assist in the early detection and management of coronary artery disease, pulmonary hypertension, and heart failure, aiming to provide more accurate and timely insights for physicians.
Our products are designed for seamless integration with common electronic health record (EHR) systems and existing diagnostic equipment. The AI/ML models typically leverage a combination of patient demographics, medical history, and standard diagnostic test results to generate comprehensive assessments.
Analytics for Life adheres to stringent regulatory standards, including HIPAA for patient data privacy and relevant medical device certifications (e.g., FDA clearance, CE Mark) for diagnostic accuracy and safety. We prioritize data security and the reliability of our AI-driven insights.
Our pricing models are typically structured to accommodate various practice sizes and healthcare systems, often including subscription-based options or per-test fees. We offer different tiers of service and can provide detailed quotes based on specific institutional needs and anticipated usage.
Analytics for Life provides comprehensive support, including initial implementation assistance, ongoing technical support, and clinical training for healthcare professionals. Our goal is to ensure that users are proficient and comfortable with our technology to maximize its benefits in patient care.
Analytics for Life is committed to continuous innovation in cardiovascular diagnostics, expanding our AI capabilities and diagnostic scope. We actively pursue strategic partnerships with leading research institutions, healthcare providers, and technology companies to enhance our offerings and ensure long-term stability and growth.

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]

CapsoVision is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) technologies for capsule endoscopy solutions. Their primary goal is to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. [7] Their flagship product, the CapsoCam Plus system, is a single-use capsule endoscope equipped with four cameras, providing […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.